Cargando…

Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers

BACKGROUND: It is essential that clinical trial participants are representative of the population under investigation. Using HIV-associated cryptococcal meningitis (CM) as a case study, we conducted a systematic review of clinical trials to determine how inclusive and representative they were both i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawrence, David S., Leeme, Tshepo, Mosepele, Mosepele, Harrison, Thomas S., Seeley, Janet, Jarvis, Joseph N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158913/ https://www.ncbi.nlm.nih.gov/pubmed/34043617 http://dx.doi.org/10.1371/journal.pntd.0009376

Ejemplares similares

Correction: Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers
por: Lawrence, David S., et al.
Publicado: (2023)

Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana
por: Kelentse, Nametso, et al.
Publicado: (2022)

High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B–Based Therapy Under Routine Care Conditions in Africa
por: Patel, Raju K K, et al.
Publicado: (2018)

HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
por: Tenforde, Mark W., et al.
Publicado: (2016)

How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?
por: Harrison, Thomas S, et al.
Publicado: (2022)

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
por: Jarvis, Joseph N, et al.
Publicado: (2022)

HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana
por: Kelentse, Nametso, et al.
Publicado: (2020)

Immune correlates of HIV-associated cryptococcal meningitis
por: Tenforde, Mark W., et al.
Publicado: (2017)

The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda
por: Lawrence, David S., et al.
Publicado: (2022)

Recent advances in managing HIV-associated cryptococcal meningitis
por: Boyer-Chammard, Timothée, et al.
Publicado: (2019)

Treatment for HIV‐associated cryptococcal meningitis
por: Tenforde, Mark W, et al.
Publicado: (2018)

Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
por: Jarvis, Joseph N., et al.
Publicado: (2013)

Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana
por: Kelentse, Nametso, et al.
Publicado: (2020)

The Lived Experience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis
por: Lawrence, David S, et al.
Publicado: (2021)

Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis
por: Stott, Katharine E, et al.
Publicado: (2022)

Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease
por: Jarvis, Joseph N., et al.
Publicado: (2020)

Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease
por: Tenforde, Mark W., et al.
Publicado: (2020)

HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long–term antiretroviral therapy in Botswana
por: Mosepele, Mosepele, et al.
Publicado: (2018)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2018)

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2019)

Cryptococcal meningitis: A neglected NTD?
por: Molloy, Síle F., et al.
Publicado: (2017)

Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION Trial
por: Jarvis, Joseph N, et al.
Publicado: (2023)

Ventriculoperitoneal shunts in non-HIV cryptococcal meningitis
por: Liu, Jia, et al.
Publicado: (2018)

Cryptococcal Meningitis in a HIV-Negative Patient
por: Barreiros, Cátia, et al.
Publicado: (2018)

Cryptococcal Meningitis in an HIV-Negative Puerperal Woman
por: Robalo Nunes, Tomás, et al.
Publicado: (2021)

Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study
por: Lawler, Kathy, et al.
Publicado: (2010)

Bartonella Infection in Immunocompromised Hosts: Immunology of Vascular Infection and Vasoproliferation
por: Mosepele, Mosepele, et al.
Publicado: (2012)

Combination Therapy for HIV-Associated Cryptococcal Meningitis—A Success Story
por: Hurt, William J., et al.
Publicado: (2021)

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis
por: Bicanic, Tihana, et al.
Publicado: (2015)

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
por: Molefi, Mooketsi, et al.
Publicado: (2015)

The Phenotype of the Cryptococcus-Specific CD4(+) Memory T-Cell Response Is Associated With Disease Severity and Outcome in HIV-Associated Cryptococcal Meningitis
por: Jarvis, Joseph N., et al.
Publicado: (2013)

Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana
por: Tenforde, Mark W., et al.
Publicado: (2020)

Risk factors in HIV/AIDS patients with cryptococcal meningitis
por: Bădicuț, Ioana, et al.
Publicado: (2014)

Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
por: Panackal, Anil A., et al.
Publicado: (2015)

1593 Predictors of Mortality for HIV-associated Cryptococcal Meningitis
por: Nimitvilai, Sireethorn, et al.
Publicado: (2014)

High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
por: Zhao, Hua-Zhen, et al.
Publicado: (2018)

Neurobehavioral Effects in HIV-Positive Individuals Receiving Highly Active Antiretroviral Therapy (HAART) in Gaborone, Botswana
por: Lawler, Kathy, et al.
Publicado: (2011)

Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults
por: Ellis, Jayne, et al.
Publicado: (2018)

Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis
por: Jarvis, Joseph N., et al.
Publicado: (2015)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
por: Ponatshego, Ponego Lloyd, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0hli4akdroqlrqr3mso89gkpq3